Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome

Bayside Health17 enrolled

Overview

The purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have Marfan Syndrome. The aorta is the major artery of the body that comes out of the heart and supplies blood to the body. We know that in people with Marfan Syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. This enlargement of the aorta can be very serious. We know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. This type of drug has never been tried in people with Marfan Syndrome.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

Conditions

Marfan Syndrome

Interventions

Coversyl (perindopril)DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18-40 * Diagnosis of Marfan Syndrome, on the basis of the Ghent Criteria Exclusion Criteria: * Age \<18, \>40 * Women of child-bearing potential not on adequate contraception * Serum creatinine of \>0.11 * A history of intolerance to ACEI * Patients on angiotensin receptor blockers * Blood pressure \>140/90mmHg * History of previous aortic surgery

Outcomes

Primary Outcomes

aortic root diameter

Time frame: 24 weeks

Secondary Outcomes

arterial stiffness

Time frame: 24 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.